Multi-Virus-Specific Donor T Cells in Treating Patients With B Cell Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, or Non-Hodgkin Lymphoma Who Have Undergone Donor Stem Cell Transplant

Inclusion Criteria

• Any patient regardless of sex or age with CD19+ B-acute lymphoblastic leukemia (ALL) undergoing allogeneic HSCT (Group A); OR any patient regardless of sex or age with CD19+ B-chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma (NHL) undergoing allogeneic HSCT (Group B)
• With minimal residual disease (MRD) or relapse post-HSCT (for the phase I dose escalation) as evidenced by polymerase chain reaction (PCR) positivity, specific cytogenetic abnormalities, an abnormal population on flow cytometry or increased blasts on bone marrow biopsy or in the peripheral blood
• MRD will be defined as detection in blood or marrow of: * Any leukemia specific marker (such as t[9:22] or t[4:11]) documented in the patient’s leukemia cells pre transplant on a post-transplant evaluation * A T-cell receptor (TCR) or immune globulin rearrangement known to be a disease marker for this patient post-transplant * A leukemia specific phenotype post-transplant at a level of >= 0.01% * Mixed donor chimerism; OR * With no evidence of ALL or CLL/NHL post-HSCT (to be included in the phase II extension)
• Patients with life expectancy >= 6 weeks
• Patients with a Karnofsky/Lansky score >= 50
• Donor human immunodeficiency virus (HIV) negative
• Patient or parent/guardian capable of providing informed consent
• Patients with bilirubin =< 2 x upper limit of normal
• Aspartate aminotransferase (AST) =< 3 x upper limit of normal
• Creatinine =< 2 x upper limit of normal for age
• Hemoglobin (Hgb) > 8.0
• Pulse oximetry of > 90% on room air
• Sexually active patients must be willing to utilize one of the more effective birth control methods for 6 months after the CTL infusion; the male partner should use a condom
• Available allogeneic CD19CAR transduced tri-virus-specific cytotoxic T lymphocytes with >=15% expression of CD19CAR determined by flow cytometry and greater than 10% killing of one or more viral antigen pulsed targets in a cytotoxicity assay at an effector:target ratio of 20:1
• Patients should have been off other investigational antiviral or antitumor therapy for one month prior to entry in this study

Exclusion Criteria

• Severe intercurrent infection
• Evidence of graft versus host disease > grade II
• Pregnant or lactating
• History of hypersensitivity reactions to murine protein-containing products
• Currently taking corticosteroids for therapy of graft-versus-host disease (GVHD)